Ipamorelin Dosage Chart.

Eight units, if you mixed a 5 mg vial with 2 mL of bacteriostatic water. That gives 2,500 mcg/mL, and one unit on a U-100 syringe is 0.01 mL, so one unit equals 25 mcg. On that same mix, 100 mcg is 4 units and 300 mcg is 12 units. Change either the vial size or the water volume and every one of those numbers changes: a 10 mg vial in the same 2 mL makes each unit 50 mcg, so 200 mcg becomes 4 units, not 8. Always recalculate from the vial in front of you rather than reusing a unit count you read somewhere.

Convention, not evidence. That figure does not appear in any published human trial, any FDA label, or any registered protocol. It seems to have propagated out of clinic and vendor protocols and hardened into a standard through repetition. The doses humans have genuinely received were much larger and intravenous: 30 to 60 mcg/kg two or three times daily in the Phase 2 bowel-surgery studies, and roughly 3 to 100 mcg/kg in the single-dose pharmacokinetic study. We flag this because many pages present 200–300 mcg as though it were a validated therapeutic dose. It is a customary one, and those are different things.

That is reasoning from growth hormone physiology, not from an ipamorelin study. Food, carbohydrate especially, raises insulin and blunts GH release, so the fasted window is meant to avoid working against that. The bedtime timing is meant to land the dose on top of the body's largest natural GH pulse, which rides on early slow-wave sleep. Both are sensible inferences and we would follow them ourselves. Neither has been tested head-to-head with ipamorelin in a trial, so treat the usual 'two hours either side of food' rule as a reasonable convention rather than something anybody proved.

The only human pharmacokinetic study used a dose-escalation design across five intravenous infusion rates, with eight healthy men at each dose level. It found a terminal half-life of about 2 hours, clearance of 0.078 L/h/kg and a steady-state volume of distribution of 0.22 L/kg. The growth hormone response is shorter than the drug's presence: GH rose as one single episode peaking at about 0.67 hours, roughly 40 minutes, then declined exponentially. So the useful signal is essentially finished within a couple of hours, which is why protocols dose more than once a day instead of relying on the drug building up. Subcutaneous injection will flatten and delay that curve, but the subcutaneous numbers have never been published in humans.

On one narrow, real measure: yes, and it is worth being precise about which. In the 1998 swine work, ipamorelin did not release ACTH or cortisol at levels significantly different from those seen after GHRH stimulation, even at more than 200 times its GH ED50, while GHRP-6 and GHRP-2 both drove ACTH and cortisol up. Note the comparator: GHRH, not placebo. And note what is not a difference. None of the secretagogues tested, ipamorelin included, affected FSH, LH, prolactin or TSH, so those four are a shared null result rather than a point in ipamorelin’s favour. The cortisol finding is a genuine advantage over those two specific peptides. It is not a general safety claim, it was never measured in humans, and it says nothing about what months of use does to glucose control or fluid balance.

Nobody has measured it. There is no human trial of ipamorelin with a body composition endpoint by any route. The nearest human data for any growth hormone secretagogue comes from a different molecule, the orally active MK-677: 24 healthy obese men were randomised, 12 to 25 mg daily for 8 weeks and 12 to placebo, and total body fat did not change significantly in the treated arm. Different drug, different population, so it does not settle the ipamorelin question, but it is a reason to keep expectations modest. A 2026 primer in the American Journal of Sports Medicine notes that the CJC-1295 plus ipamorelin muscle findings are limited to animal studies, and that indications, dosing, frequency and duration of treatment remain unknown.

No. Searching DailyMed, the FDA's official label repository, for ipamorelin returns zero results: no approved product, no approved label. Its clinical development targeted postoperative ileus and it stopped there. The Phase 2 proof-of-concept trial in 114 evaluable bowel-resection patients missed its primary endpoint: median time to first tolerated meal was 25.3 hours on ipamorelin versus 32.6 hours on placebo, p = 0.15. A larger 320-patient Phase 2 dose-finding study run by Helsinn completed in 2014 and never posted results. Everything sold today sits outside that pathway as research-grade material.

Yes. Ipamorelin is a growth hormone secretagogue and ghrelin receptor agonist, which places it in section S2 of the WADA Prohibited List (peptide hormones, growth factors, related substances and mimetics), and everything in S2 is prohibited at all times, in and out of competition. There is no therapeutic-use loophole for a compound with no approved indication. If you are tested under the WADA code, or under any national or collegiate body that adopts it, this is disqualifying regardless of dose or route.

Watch both, but keep the reasoning honest. Those warnings come from FDA labelling for injected growth hormone, which lists fluid retention (oedema, joint and muscle aches, and nerve compression syndromes including carpal tunnel and paraesthesias) as usually transient and dose dependent, and separately notes that somatropin may decrease insulin sensitivity, particularly at higher doses. Ipamorelin is not somatropin: it prompts your own pituitary, which is self-limiting in a way that injecting GH is not. But it works through the same downstream axis, so those are the sensible things to monitor. Puffy hands and a fasting glucose that has quietly drifted upward are your two cheapest early warnings.